EPISODE · Apr 30, 2026 · 6 MIN
What To Expect After China’s First siRNA Firm Went Public
from Citeline Podcasts · host Norstella
In this episode of the China biopharma English-language podcast, Xu Hu talks about the siRNA area, including possible industry and R&D environment changes for Chinese firms developing these therapies and trends in deals of China-originated siRNA assets this year. Story link: Chinese siRNA Contenders Set For Transitions, Deals In 2026
Embed this episode
Ready to play
What To Expect After China’s First siRNA Firm Went Public
No transcript for this episode yet
Similar Episodes
No similar episodes found.